Newer drugs and targets in tuberculosis

Harish Thanu Subramanian, K. Meena Kumari, V. Amberkar Mohan Babu

Research output: Contribution to journalArticle

Abstract

In the year 2013, nine million people suffered from tuberculosis. Around 1.5 million people (men, woman and children) died due to tuberculosis. About 1.1 million people with HIV developed tuberculosis. The major drawbacks of tuberculosis treatment in a patient are multidrug resistant tuberculosis (MDR-TB) and extensively drug resistant tuberculosis (XDR-TB). Recently newer drugs and targets have been the key focus of research in finding the permanent cure for tuberculosis. The FDA has recently approved a new tuberculosis drug bedaquiline. The drugs under trials are delamanid, pretomanid, sutezolid and SQ109. Drugs in preclinical development showing promising results are benzothiazinone, spectinamide, capuramycin, TBI-166 (Riminophenazines antibiotic). The various lead compounds which showed promising activity against mycobacterial tuberculosis are SPR113, cyclopeptides, ruthenium complexes, leucyl-t-RNA inhibitors, inhA inhibitors. The various hits during drug discovery shown to have effect against tuberculosis infection are ATP synthesis inhibitors, RNA polymerase inhibitors, energy metabolism inhibitors, menaquinone inhibitors and malate synthesis inhibitors. Biologics have shown to improve the treatment outcome in tuberculosis but are still in trial or in drug development. They are immunoxel, HE2000, Oral mycobactriumvaccae(V7), TGF-Inhibition + COX-2 inhibition, IL-4 antibody. Some of the old drugs which have found to be effective against tuberculosis are: High dose rifampin, statins, meropenem+clavulanate, nitazoxanide.

Original languageEnglish
Pages (from-to)831-838
Number of pages8
JournalResearch Journal of Pharmaceutical, Biological and Chemical Sciences
Volume7
Issue number3
Publication statusPublished - 01-01-2016

Fingerprint

Tuberculosis
Pharmaceutical Preparations
nitazoxanide
meropenem
Extensively Drug-Resistant Tuberculosis
bedaquiline
Lead compounds
Vitamin K 2
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Cyclic Peptides
Clavulanic Acid
Ruthenium
DNA-Directed RNA Polymerases
Rifampin
Biological Products
Interleukin-4
Multidrug-Resistant Tuberculosis
Adenosine Triphosphate
Drug Discovery
RNA

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

@article{a547410d1028418d8fae962be07c22c8,
title = "Newer drugs and targets in tuberculosis",
abstract = "In the year 2013, nine million people suffered from tuberculosis. Around 1.5 million people (men, woman and children) died due to tuberculosis. About 1.1 million people with HIV developed tuberculosis. The major drawbacks of tuberculosis treatment in a patient are multidrug resistant tuberculosis (MDR-TB) and extensively drug resistant tuberculosis (XDR-TB). Recently newer drugs and targets have been the key focus of research in finding the permanent cure for tuberculosis. The FDA has recently approved a new tuberculosis drug bedaquiline. The drugs under trials are delamanid, pretomanid, sutezolid and SQ109. Drugs in preclinical development showing promising results are benzothiazinone, spectinamide, capuramycin, TBI-166 (Riminophenazines antibiotic). The various lead compounds which showed promising activity against mycobacterial tuberculosis are SPR113, cyclopeptides, ruthenium complexes, leucyl-t-RNA inhibitors, inhA inhibitors. The various hits during drug discovery shown to have effect against tuberculosis infection are ATP synthesis inhibitors, RNA polymerase inhibitors, energy metabolism inhibitors, menaquinone inhibitors and malate synthesis inhibitors. Biologics have shown to improve the treatment outcome in tuberculosis but are still in trial or in drug development. They are immunoxel, HE2000, Oral mycobactriumvaccae(V7), TGF-Inhibition + COX-2 inhibition, IL-4 antibody. Some of the old drugs which have found to be effective against tuberculosis are: High dose rifampin, statins, meropenem+clavulanate, nitazoxanide.",
author = "Subramanian, {Harish Thanu} and {Meena Kumari}, K. and {Amberkar Mohan Babu}, V.",
year = "2016",
month = "1",
day = "1",
language = "English",
volume = "7",
pages = "831--838",
journal = "Research Journal of Pharmaceutical, Biological and Chemical Sciences",
issn = "0975-8585",
publisher = "RJPBCS",
number = "3",

}

Newer drugs and targets in tuberculosis. / Subramanian, Harish Thanu; Meena Kumari, K.; Amberkar Mohan Babu, V.

In: Research Journal of Pharmaceutical, Biological and Chemical Sciences, Vol. 7, No. 3, 01.01.2016, p. 831-838.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Newer drugs and targets in tuberculosis

AU - Subramanian, Harish Thanu

AU - Meena Kumari, K.

AU - Amberkar Mohan Babu, V.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - In the year 2013, nine million people suffered from tuberculosis. Around 1.5 million people (men, woman and children) died due to tuberculosis. About 1.1 million people with HIV developed tuberculosis. The major drawbacks of tuberculosis treatment in a patient are multidrug resistant tuberculosis (MDR-TB) and extensively drug resistant tuberculosis (XDR-TB). Recently newer drugs and targets have been the key focus of research in finding the permanent cure for tuberculosis. The FDA has recently approved a new tuberculosis drug bedaquiline. The drugs under trials are delamanid, pretomanid, sutezolid and SQ109. Drugs in preclinical development showing promising results are benzothiazinone, spectinamide, capuramycin, TBI-166 (Riminophenazines antibiotic). The various lead compounds which showed promising activity against mycobacterial tuberculosis are SPR113, cyclopeptides, ruthenium complexes, leucyl-t-RNA inhibitors, inhA inhibitors. The various hits during drug discovery shown to have effect against tuberculosis infection are ATP synthesis inhibitors, RNA polymerase inhibitors, energy metabolism inhibitors, menaquinone inhibitors and malate synthesis inhibitors. Biologics have shown to improve the treatment outcome in tuberculosis but are still in trial or in drug development. They are immunoxel, HE2000, Oral mycobactriumvaccae(V7), TGF-Inhibition + COX-2 inhibition, IL-4 antibody. Some of the old drugs which have found to be effective against tuberculosis are: High dose rifampin, statins, meropenem+clavulanate, nitazoxanide.

AB - In the year 2013, nine million people suffered from tuberculosis. Around 1.5 million people (men, woman and children) died due to tuberculosis. About 1.1 million people with HIV developed tuberculosis. The major drawbacks of tuberculosis treatment in a patient are multidrug resistant tuberculosis (MDR-TB) and extensively drug resistant tuberculosis (XDR-TB). Recently newer drugs and targets have been the key focus of research in finding the permanent cure for tuberculosis. The FDA has recently approved a new tuberculosis drug bedaquiline. The drugs under trials are delamanid, pretomanid, sutezolid and SQ109. Drugs in preclinical development showing promising results are benzothiazinone, spectinamide, capuramycin, TBI-166 (Riminophenazines antibiotic). The various lead compounds which showed promising activity against mycobacterial tuberculosis are SPR113, cyclopeptides, ruthenium complexes, leucyl-t-RNA inhibitors, inhA inhibitors. The various hits during drug discovery shown to have effect against tuberculosis infection are ATP synthesis inhibitors, RNA polymerase inhibitors, energy metabolism inhibitors, menaquinone inhibitors and malate synthesis inhibitors. Biologics have shown to improve the treatment outcome in tuberculosis but are still in trial or in drug development. They are immunoxel, HE2000, Oral mycobactriumvaccae(V7), TGF-Inhibition + COX-2 inhibition, IL-4 antibody. Some of the old drugs which have found to be effective against tuberculosis are: High dose rifampin, statins, meropenem+clavulanate, nitazoxanide.

UR - http://www.scopus.com/inward/record.url?scp=84973344402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973344402&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84973344402

VL - 7

SP - 831

EP - 838

JO - Research Journal of Pharmaceutical, Biological and Chemical Sciences

JF - Research Journal of Pharmaceutical, Biological and Chemical Sciences

SN - 0975-8585

IS - 3

ER -